PTAB denies Novartis petitions to review Plexxikon patents
The US Patent and Trademark Office (USPTO) has declined to hear two petitions filed by Switzerland-based Novartis to review two patents owned by drug discovery company Plexxikon.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
7 April 2026 According to the settlement, MSN can maintain its challenge to several Bausch patents, while the details around potential product launch timings are unknown.
1 April 2026 After years of strict patent rules, Argentina is changing course. New IP reforms are putting the country back on the map, but how companies handle the transition will matter.
